Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy most frequently involving the nasal cavity and upper aerodigestive tract, although it may present in other extranodal ...

Invariant natural killer T (iNKT) cells represent a unique lymphocyte subset that bridges innate and adaptive immunity. Their development originates in the thymus from double‐positive precursor cells, ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. Now ...

Study data show stronger Ph+ acute lymphoblastic leukaemia immune activation with dasatinib plus blinatumomab than with ponatinib combinations, highlighting sustained natural killer cell responses.

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...

“CAR-T cells are very potent cells. However, the most surprising finding in our work is that these potent cells are strongly inhibited in tumor models that recapitulate the complexity of the tumor ...

San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease. Natural killer T ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...

Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a ...

Detailed price information for Cytomed Therapeutics Limited (GDTC-Q) from The Globe and Mail including charting and trades.